NEW YORK (GenomeWeb News) – Canadian data extraction specialty company Diagnos will partner with Ontario’s University of Queens to develop a biomarker-based test and a new algorithm to help doctors diagnose follicular lymphoma, the company said today.
Under the first phase of the project, the company will work with the University of Queens’ Cancer Research Institute to develop an automated approach for distinguishing follicular lymphoma from benign lymphoid infiltrates using small samples. The company said it plans to increase its accuracy by using morphological analysis along with immunohistochemistry.
In the second phase of research, the company will use its data extraction technologies to find protein or nucleic acid biomarkers that can be used to better diagnose and predict treatment for this type of lymphoma.
The company said it selected follicular lymphoma because it currently is a difficult subtype to diagnose with accuracy and confidence.